Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
Go back to Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.26 | 52 Week High | $9.58 | |||
| Open | $2.26 | 52 Week Low | $2.34 | |||
| Day High | $2.26 | P/E | N/A | |||
| Day Low | $2.26 | EPS | $-0.34 | |||
| Volume | 16,267 | |||||
